Jagsonpal Pharmaceuticals Ltd logo

Jagsonpal Pharmaceuticals Ltd

NSE: JAGSNPHARM BSE: 507789

₹216.15

-0.58 (0.27%)

Sun, 22 Nov 2026, 06:21 pm

mtf coin illustrationMTF 5xInvest in Jagsonpal Pharmaceuticals Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)1427.21
PE Ratio32.46
Dividend1.16
Health TechnologyHealth Technology
Pharmaceuticals: GenericPharmaceuticals: Generic
24.5K24.5K

Jagsonpal Pharmaceuticals Analysis

dividend

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (14.2x coverage).
  • Jagsonpal Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • No dividend growth in 10 years.
  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Jagsonpal Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

thumbs up icon

Pros

  • Jagsonpal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (688.2%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 23.3x debt.
  • Jagsonpal Pharmaceuticals's cash and other short term assets cover its long term commitments.
  • The level of debt compared to net worth has been reduced over the past 5 years (36.1% vs 4.1% today).
  • Jagsonpal Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
  • Jagsonpal Pharmaceuticals's level of debt (4.1%) compared to net worth is satisfactory (less than 40%).
thumbs up icon

Cons

  • High level of physical assets or inventory.

management

thumbs up icon

Pros

  • The tenure for the Jagsonpal Pharmaceuticals board of directors is about average.
  • Rajpal P.'s remuneration is lower than average for companies of similar size in India.
  • Rajpal P.'s compensation has been consistent with company performance over the past year, both up more than 20%.
  • The average tenure for the Jagsonpal Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
thumbs up icon

Cons

    misc

    thumbs up icon

    Pros

      thumbs up icon

      Cons

      • Jagsonpal Pharmaceuticals is not covered by any analysts.
      • Jagsonpal Pharmaceuticals has significant price volatility in the past 3 months.

      past

      thumbs up icon

      Pros

      • Jagsonpal Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (212.6% vs 8.5%)
      • Jagsonpal Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
      • Jagsonpal Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
      • Jagsonpal Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (212.6% vs 22.7%).
      thumbs up icon

      Cons

      • Jagsonpal Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
      • Jagsonpal Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

      value

      thumbs up icon

      Pros

      • Jagsonpal Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
      • Jagsonpal Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
      • Jagsonpal Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
      • Jagsonpal Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
      • Jagsonpal Pharmaceuticals is good value based on earnings compared to the India market.
      • 507789 outperformed the Market in India which returned -14.5% over the past year.
      • BSE:507789 is up 16.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
      • BSE:507789 is up 16.9% outperforming the market in India which returned 8% over the past month.
      thumbs up icon

      Cons

      • 507789 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
      pocketful logo lightpocketful logo dark
      PricingBecome a Partner
      search icon
      /

      No results for ''

      Popular search

      • popular search iconSuzlon Energy Ltd
      • popular search iconIndian Railway Finance Corporation Ltd
      • popular search iconTata Motors Ltd
      • popular search iconTata Steel Ltd
      • popular search iconRail Vikas Nigam Ltd

      Recent search

          Log In
          search icon

          No results for ‘’

            Popular search

            • popular search iconSuzlon Energy Ltd
            • popular search iconIndian Railway Finance Corporation Ltd
            • popular search iconTata Motors Ltd
            • popular search iconTata Steel Ltd
            • popular search iconRail Vikas Nigam Ltd
            • popular search iconReliance Industries Ltd
            pocketful logo lightpocketful logo dark
            • Pricing
            • Become a Partner
            Log In
            • home icon
            • arrow iconstocks
            • arrow iconjagsonpal pharmaceuticals ltd
            • arrow iconanalysis
            • Overview
            • Analysis
            • Financials
            • Ratios
            • shareholding
            • Technical Analysis
            • Corporate Actions
            • Peer Comparison
            • About
            • Deals
            • News
            • FAQs

            Open Your Free Demat Account Now!

            Step into a world of zero fees and limitless opportunities!

            pocketful logo
            • Quick Links

              • Open Demat Account
              • Pocketful Web
              • Pocketful App
              • Pricing
              • Authorised Person
              • Pocketful Calculators
              • Compliance Links
            • Pages

              • Tools
              • Blogs
              • ETF Screener
              • IPO
              • ETF
              • Bonds
              • Index Heat Map
            • Products

              • Stocks
              • Commodity
              • Subscription
              • Free Stock Screener
              • Pocketful GPT
              • MTF
              • Mutual Funds
            • Company

              • About us
              • Contact us
              • Terms and Conditions
              • Policies & Procedures
              • Privacy Policy
              • Disclosure
              • Careers
            • Socials

              • Facebook iconFacebook
              • Twitter iconTwitter
              • Instagram iconInstagram
              • LinkedIn iconLinkedIn
              • Youtube iconYoutube

            2022-25 Pocketful. All rights reserved, Built with in India

            Version -5.76

            app image 1app image 2

            Stocks:

            AllABCDEFGHIJKLMNOPQRSTUVWXYZ

            Explore

            Calculators
            Popular Calculators
            Group Stocks
            Asset Management Companies
            Popular Stocks
            Indian Indices
            Sector Wise Stocks
            IPO
            Share Market
            Best MF Schemes
            Platforms
            Resources
            Gold Rates in Top Cities
            Silver Rates in Top Cities

            Others:

            NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

            Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800